CCM
GNMK

Consonance Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Consonance Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,480,163
Closed -$65.4M – 48
2020
Q4 		$65.4M Sell
4,480,163
-819,700
-15% -$10.9M 6.11% 6
2020
Q3 		$75.3M Sell
5,299,863
-1,594,618
-23% -$24.4M 9.17% 2
2020
Q2 		$101M Buy
+6,894,481
New +$70M 6.08% 4

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Consonance Capital Management's GNMK Position: Q1 2021 in Review

Consonance Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 4,480,163 shares — an estimated $65.4M sold.

Consonance Capital Management first reported a position in GNMK in Q2 2020 and held it in 3 quarters. The position peaked at $101M in Q2 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Consonance Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Consonance Capital Management sold 4,480,163 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $65.4M.
  • Consonance Capital Management first reported a position in GenMark Diagnostics, Inc in Q2 2020 and held it in 3 quarters.
  • Consonance Capital Management's GenMark Diagnostics, Inc position peaked at $101M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.